Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.72 |
| ▸ | RAB9A | P51151 | 8/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 3/20 | 0.66 |
| ▸ | MMP9 | P14780 | 3/20 | 0.66 |
| ▸ | MMP8 | P22894 | 3/20 | 0.66 |
| ▸ | MMP13 | P45452 | 2/20 | 0.66 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.66 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 4/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28051575 | 0.98 | NPC1 (0.70) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL13942807 | 0.98 | NPC1 (0.70) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL2178266 | 0.90 | NPC1 (0.88) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL29386825 | 0.90 | NPC1 (0.88) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL24295036 | 0.88 | NPC1 (0.84) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL22499602 | 0.86 | NPC1 (0.81) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL2763186 | 0.86 | CA12 (0.59) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL17393603 | 0.85 | NR1H4 (0.61) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL2252555 | 0.85 | NPC1 (0.92) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL6503052 | 0.84 | HPSE (0.87) | NPC1RAB9AKDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| CN-105646591-B | It is a kind of using brominated benzimidazole as blue light complex of iridium of cyclic metal complexes and preparation method thereof | 福建师范大学 | 2018-10-19 | — | — | CN | claimed |
| CN-117304919-B | Organic fluorescent sensing array for selectively distinguishing and detecting sarin and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| CN-119143678-A | Fluorescent molecule for rapidly measuring excitation light spot size and light intensity distribution and preparation method thereof | 中国科学院化学研究所 | 2024-12-17 | — | — | CN | disclosed |
| CN-118496219-A | Organic small molecule photoresist and preparation method and application thereof | 中国科学院化学研究所 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024137505-A2 | METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-117304919-A | Organic fluorescent sensing array for selectively distinguishing and detecting sarin and preparation method thereof | 中国科学院化学研究所 | 2023-12-29 | — | — | CN | disclosed |
| CN-116924995-A | Method for synthesizing benzimidazole compound by catalyzing L-phenylalanine | 宁夏师范学院 | 2023-10-24 | — | — | CN | disclosed |
| CN-114989094-B | Method for synthesizing benzimidazole derivative by visible light catalysis | 云南民族大学 | 2023-09-29 | — | — | CN | disclosed |
| WO-2008140239-A1 | IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-20 | — | — | WO | disclosed |
| US-20080265746-A1 | PHENANTHROLINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | Yen, Feng Wen (TW) | 2008-10-30 | — | — | US | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007088148-A1 | DERIVATIVES OF THIOPHENE CARBOXILIC ACID AS ANTIVIRAL AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007039146-A1 | 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
| US-5486517-A | Benzimidazoles and imidazopyridines as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995030659-A1 | BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINERGIC AGENTS, ESP. SELECTIVE FOR THE DOPAMINE D3 RECEPTOR | WARNER-LAMBERT COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | NPC1 989/4885RAB9A 2214/4885GAA 382/4885 |
| US-20080265746-A1 | PHENANTHROLINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | AHR, HAX1, ARNT | NPC1 2545/4885RAB9A 1450/4885GAA 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.